Submitted by Anonymous (not verified) on 14 August 2023 - 15:55
Human medicines European public assessment report (EPAR): Aimovig, erenumab, Migraine Disorders, Date of authorisation: 26/07/2018, Revision: 11, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Aimovig, erenumab, Migraine Disorders, Date of authorisation: 26/07/2018, Revision: 11, Status: Authorised